Navigation Links
PRX in Medical News

Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009

... WOODCLIFF LAKE, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today reported results for the second quarter ended June 27, 2009. For the second quarter ended June 27, 2009, Par reported total revenues o...

Par Pharmaceutical to Host Second Quarter 2009 Earnings Conference Call on August 4 at 9:00 am

... WOODCLIFF LAKE, N.J., July 15 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) announced today that it will host a conference call and live webcast on Tuesday, August 4, 2009 at 9:00 am EDT to review results for the second quar...

Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.

... WOODCLIFF LAKE, N.J., June 12 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that Thomas P. Rice has been elected to the company's board of directors. Mr. Rice was also appointed to the Audit Committee and th...

MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip

...the tongue. MonoSol Rx and its partner Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: prx ), are seeking FDA approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemothera...

Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)

... WOODCLIFF LAKE, N.J., June 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that it began shipping calcitonin-salmon nasal spray to the trade. Calcitonin-salmon nasal spray is a generic version of Novartis' ...

Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009

...ins and Higher Sales of Select Generic Products WOODCLIFF LAKE, N.J., May 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today reported results for the first quarter ended March 28, 2009. Par reported total revenues of $204.0 million and net income of $16.1 milli...

Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR

... WOODCLIFF LAKE, N.J., April 21 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) ("Par") today announced it has entered into a settlement agreement with Reliant Pharmaceuticals, Inc. ("Reliant") that resolves patent litigation re...

Strativa Pharmaceuticals Provides Product Pipeline Update

...-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: prx ), today provides an update on two of its pipeline products. Ondansetron Orally Dissolving Film Strip On April 7, 2009, Strativa submitt...

MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip

...ving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: prx ), today announced the submission on April 7, 2009 of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the orally disso...

Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical

...-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: prx ), today announced it has acquired the worldwide rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray from QOL Medical LLC. Nascobal Nasal Spray ...
PRX in Medical Technology

Strativa Pharmaceuticals Provides Product Pipeline Update

...-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: prx ), today provides an update on two of its pipeline products. Ondansetron Orally Dissolving Film Strip On April 7, 2009, Strativa submitt...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that its development partner, Alfacell Corporation (Nasdaq: ACEL ) reported that the preliminary statistical analysis of data from ...

Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis

...KE, N.J., April 21 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that its development partner, BioAlliance Pharma reported preliminary, top-line results for a Phase III study of Loramyc(R) (miconaz...

Chinese SFDA Grants Immtech Fast Track Status

...e and effective drugs to market." In June 2007, Immtech entered into an exclusive licensing agreement with Par Pharmaceutical Companies, Inc. (NYSE: prx ) under which Par will receive commercialization rights in the U.S. to pafuramidine for the treatment of PCP in AIDS patients. About Immtech Pharmace...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

... WOODCLIFF LAKE, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced it had begun shipping metoprolol succinate extended release 50 mg tablets. As previously announced, in November 2006 Par entered int...

Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases

...Drugs VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox's prx 302. The Journal of the National Cancer Institute ("JNCI") has published the work conducted by Dr. Sam Denmeade and his team at Johns Hopkins Universi...
PRX in Biological News

Research explores role of hydrogen peroxide in cell health

...rx) helps control levels of the agent. The role of prx is important because if the levels of hydrogen per...at leads to cancer, diabetes and other disease. prx actually has a dual role in the process. Its usual... to water. But if levels get dangerously high and prx needs help it becomes inactive in its converting ...
PRX in Biological Technology

Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA

...-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: prx ), today announced that its development partner, BioAlliance Pharma, has submitted a New Drug Application (NDA) to the Food and Drug Administration (F...

Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA

...-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: prx ), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film...

Par Pharmaceutical to Present at the 27th Annual J.P. Morgan Healthcare Conference

... WOODCLIFF LAKE, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) will be presenting at the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 3:00 pm PST at the Westin St. Francis Hotel. ...

Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film

...AKE, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that its development partner, MonoSol Rx, reported the successful completion of all pivotal bioequivalence studies for a thin film f...

Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension

... WOODCLIFF LAKE, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that the U.S. District Court for the District of New Jersey last night granted AstraZeneca Pharmaceuticals' motion for a temporary r...

Par Pharmaceutical Reports Second Quarter 2008 Results

...hes Should Contribute Significantly in Second Half WOODCLIFF LAKE, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced results for the second quarter ended June 28, 2008. Second Quarter and Six Month Results For the second quarter ended June 28, 2...

Par Pharmaceutical to Host Second Quarter 2008 Results Conference Call on August 8 at 9:00 am

... WOODCLIFF LAKE, N.J., July 29 /PRNewswire-FirstCall/ - Par Pharmaceutical Companies, Inc. (NYSE: prx ) announced today that it will host a conference call and live webcast on Friday, August 8, 2008 at 9:00 am ET to review results for the second quarte...

Par Pharmaceutical to Launch meclizine HCL Tablets

... WOODCLIFF LAKE, N.J., July 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that it will commence shipment of 12.5mg and 25mg meclizine HCl tablets immediately. At this time, Par believes it is the exclusive ...

Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules

...Shipping Dronabinol Soft Gel Capsules Immediately WOODCLIFF LAKE, N.J., June 30 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: prx ) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dronabin...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...SDAQ: NUVO ) PAR PHARMACEUTICAL COS INC. (NYSE: prx ) SANGAMO BIOSCIENCES INC. (NASDAQ: SGMO ) SCIE...ASDAQ: HOLX ) PAR PHARMACEUTICAL COS INC (NYSE: prx ) SUCAMPO PHARMACEUTICALS INC (NASDAQ: SCMP ) V...ASDAQ: MYGN ) PAR PHARMACEUTICAL COS INC (NYSE: prx ) PHARMASSET INC (NASDAQ: VRUS ) SHIONOGI & CO ...
PRX in Biological Products

Rabbit Anti-Peroxiredoxin 1 Polyclonal Antibody, Unconjugated from GeneTex

Description:...throughout all the kingdoms. Among them, mammalian prx consists of 6 different members grouped into typic...Prx, and 1-Cys Prx. Except Prx6 belonging to 1-Cys prx subgroup, the other five 2-Cys prx isotypes have the thioredoxin-dependent peroxidase...
Company:GeneTex
Other Tags
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Prostate cancer patients ... receive less effective treatment and die sooner if they ... analyzed data from more than 41,200 American men who ... 2007. They followed them through 2009. Nearly 1,900 of ... two years before their prostate cancer was discovered. ...
(Date:7/11/2014)... Sacramento, CA (PRWEB) July 11, 2014 ... Luke Bryan Tickets at the Sleep Train Amphitheatre in ... few venues that can compare to what the Sleep Train ... countless musical events and special attractions over the course of ... October 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
(Date:7/11/2014)... The “Proteomics Market by Technology ... Surface Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents ... and studies the major market drivers, restraints, and ... Rest of the World (RoW). , The proteomics ... few years, mainly due to the increasing need ...
(Date:7/11/2014)... many years scientists have been trying to unravel mechanisms ... those cells that generate all blood cells including our ... is difficult because they can only be found in ... recapitulated in a culture dish. Now a group of ... Claudia Waskow (Technische Universitt Dresden) was able to generate ...
Breaking Medicine News(10 mins):Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Opening-up the stem cell niche 2
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market ... Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... & Finance), and Geography - Global Trends & Forecasts ... Fingerprint Sensors Market is projected to cross $14.35 Billion ... from 2014 to 2020. Browse more than ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... A Chinese Top 5 smartphone OEM has selected FPC1021 for ... in October 2014.   FPC is proud to ... which has a planned date for the start of mass ... this phone of 3 million units. The Chinese OEM wants ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
Other Contents